% of Cases treated with Surgery
| Country average (population) | Country average (country) | England | Scotland | Wales1 | Northern Ireland | Republic of Ireland | |
|---|---|---|---|---|---|---|---|
| All invasive xnmsc | 48.7% | 47.2% | 49.6% | 40.1% | 48.1% | 50.8% | |
| All xnmsc 0-24 | 51.7% | 52.4% | 51.8% | 47.8% | 50.6% | 59.5% | |
| All xnmsc 25-59 | 66.1% | 64.5% | 66.8% | 59.1% | 68.0% | 64.2% | |
| All xnmsc 60-79 | 48.7% | 46.5% | 49.8% | 39.2% | 47.3% | 49.7% | |
| All xnmsc 80+ | 30.1% | 29.7% | 30.8% | 21.4% | 31.2% | 35.5% | |
| Haematology | 6.5% | 7.7% | 6.4% | 5.8% | 6.6% | 11.9% | |
| Head and Neck | 54.0% | 52.6% | 55.0% | 43.3% | 59.9% | 52.3% | |
| Lower GI | 67.5% | 68.4% | 67.8% | 59.6% | 71.3% | 75.0% | |
| Upper GI | 36.9% | 36.7% | 38.7% | 17.6% | 37.9% | 52.8% | |
| HPB | 32.1% | 29.6% | 34.0% | 10.2% | 32.2% | 41.8% | |
| Trachea, Bronchus & Lung | 26.1% | 22.8% | 28.1% | 13.1% | 21.1% | 28.8% | |
| Melanoma of skin | 96.7% | 90.8% | 97.2% | 96.7% | 97.9% | 71.5% | |
| Breast | 76.4% | 77.3% | 76.4% | 74.5% | 79.0% | 79.2% | |
| Cervix | 63.4% | 58.8% | 64.8% | 53.6% | 60.6% | 56.1% | |
| Other Female Genitals | 75.8% | 73.7% | 76.7% | 68.0% | 76.6% | 73.6% | |
| Prostate | 22.4% | 16.8% | 23.7% | 13.9% | 17.5% | 12.0% | |
| Kidney | 59.8% | 59.7% | 60.7% | 48.3% | 59.6% | 70.0% | |
| Bladder | 85.6% | 85.2% | 86.0% | 79.9% | 85.4% | 89.6% | |
| Brain and CNS | 51.4% | 50.3% | 52.0% | 47.6% | 43.9% | 57.7% | |
| Thyroid & other endocrine glands | 87.5% | 84.2% | 88.3% | 80.5% | 89.0% | 78.9% | |
| CUP | 13.2% | 11.6% | 14.1% | 4.7% | 12.7% | 14.8% | |
| Other invasive cancer | 56.7% | 53.2% | 58.1% | 45.6% | 53.0% | 55.9% | |
| Breast in situ | 87.0% | 87.7% | 86.7% | 91.8% | 87.0% | 85.4% | |
| Cervix in situ | 88.0% | 70.4% | 90.1% | 98.3% | 79.7% | 13.5% | |
| Other tumours | 63.0% | 60.4% | 63.0% | 71.1% | 58.8% | 48.8% | |
| Non-Melanoma Skin Cancer | 50.1% | 55.5% | 47.5% | 91.5% | 39.5% | 43.6% |